Zydus Lifesciences launches overactive bladder medication in the US
Zydus Lifesciences Ltd. has introduced a new medication for overactive bladder (OAB) treatment in the US. The tablet, named Mirabegron Extended-Release, is available in a 25mg dosage. According to the company's statement, it aims to alleviate symptoms such as urge urinary incontinence, and high urinary frequency associated with an overactive bladder. Punit Patel, CEO Americas of Zydus Lifesciences, emphasized, "This is a significant launch for us which will strengthen our growth plans in the US market in the current fiscal."
Production and future plans for medicine
The production of the Mirabegron Extended-Release tablets will occur at Zydus Lifesciences' formulation manufacturing facility, located in Ahmedabad. The company had previously secured final approval from the United States Food and Drug Administration (USFDA) to market these tablets. Zydus also plans to introduce a 50mg version of the tablet in the future, further expanding its product range. The firm aims to enhance patient care while also bolstering its presence in the American pharmaceutical sector.
Mirabegron's market performance and Zydus's future prospects
According to IQVIA data, the Mirabegron Extended-Release tablets had annual sales of $2.4 billion in the US, for the 12 months ending February 2024. To date, Zydus has received 393 approvals and submitted over 460 Abbreviated New Drug Applications (ANDAs) since FY04. Despite a slight dip in shares by 1.28% to ₹925 each on Friday, April 19, the company's stock has seen a substantial gain of 78.93% over the past year.
